Home
overview

Dear Colleague,

The completion of the sequencing of the human and other genomes has further increased the importance of recombinant protein production both for basic research and therapeutic applications. Although technology development has made it possible to produce large quantities of recombinant proteins for structural biology, bottlenecks still exist, particularly for membrane proteins. Paradoxically, more than 70% of the current drug targets are based on this class of proteins.

The Global Protein Summit will be an excellent opportunity to hear about the latest developments bringing together expertise in protein expression, protein purification and structural biology. World leaders will present the latest development in expression systems and their applications on important drug targets.

The event provides a genuine opportunity to get an overview of research activities in both academia and industry and also sets the stage for unique opportunities of networking. I therefore encourage anyone in academia or industry with an interest in basic research and/or therapeutic applications on recombinant proteins to attend.


Dr Kenneth Lundstrom
Chief Scientific Officer, BioXtal


This conference will follow on from the success of last year's event. The event will focus on the new and emerging expression systems, the challenges and solutions covering transport protein structures, automation in cell culture, membrane expression and purification.

Protein expression used for the large-scale manufacturing of recombinant protein therapeutics and the production of target protein for drug screening has become central to the biotechnology and pharmaceutical drug discovery and development process. Other applications of protein expression for both structural studies and protein interactions have grown with the development of structural genomic and proteomic research. However, as more genomic information has become available the logistics of protein expression have become more problematic.

The conference will provide delegates with an overview of the current market. The event will examine the issues faced by scientists involved in maximising the efficiency of protein expression and overcoming the hurdles involved in purification, providing a valuable opportunity for researchers to get together to discuss emerging technologies and both practical and theoretical ideas.

A unique opportunity to learn from leading industry experts including:
  • Dr Tauseef Butt, President, LifeSensors
  • Dr Stephen Chambers, Director, Gene Expression, Vertex Pharmaceuticals
  • Dr Amanda Proudfoot, Head, Protein Biochemistry Department, Serono
  • Dr Kenneth Lundstrom, Chief Scientific Officer, BioXtal
  • Dr Bram Bout, Vice President, Protein Production, Crucell
  • Dr Paul Ramage, Group Leader, Protein Preparation, Protein Structure Unit, Novartis Institutes for Biomedical Research
  • Dr Stefan Schmidt, Team Leader, Protein Science, AstraZeneca
  • Dr Ian Hunt, Laboratory Head, Novartis Institutes for Biomedical Research
  • Dr Stephen Irving, Senior Principal Scientist, Pfizer
  • Dr Kairat Madin, Senior Scientist, Protein Expression, Roche Diagnostics

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Kenneth Lundstrom

Kenneth Lundstrom, Chief Scientific Officer, BioXtal

9:10 FREEDOM OF EXPRESSION

Stephen Chambers

Stephen Chambers, Director, Gene Expression, Vertex Pharmaceuticals

  • Design of experiment
  • Miniaturised protein expression
  • Automated protein purification
  • Quantitative analysis
  • Applications
  • Proteins as commodities
  • 9:50 THE CHALLENGES OF SUPPLYING PROTEINS FOR STRUCTURAL BIOLOGY

    Stephen Irving

    Stephen Irving, Senior Principal Scientist, Pfizer

  • Comparison of different expression systems and success rates across a diverse set of proteins
  • Opportunities enabled by increased throughput technologies
  • Data accumulated from 10 years experience
  • 10:30 Morning Coffee

    10:50 PROTEINS FOR BIOSTRUCTURAL RESEARCH

    Glenn Dale

    Glenn Dale, Director, Biological Research, Morphochem

  • Expression systems
  • Refolding
  • Point mutations
  • Protein engineering
  • 11:30 FROM GENE TO PROTEIN

    Grant Cameron

    Grant Cameron, Commercial Director, NextGen Sciences

  • The matrix approach – managing information
  • Plan, co-ordinate execute and monitor cloning and expression strategies
  • Linking virtual experiments with those in the laboratory
  • The need for automation
  • Meeting different throughput requirements
  • 12:10 Networking Lunch

    13:40 CELL-FREE TRANSLATION FOR RECOMBINANT PROTEIN EXPRESSION

    Kairat Madin

    Kairat Madin, Senior Scientist, Protein Expression, Roche Diagnostics

    Details to be confirmed

    14:20 THE USE OF CELL-FREE, BACTERIAL AND BACULOVIRUS-BASED SYSTEMS TO PRODUCE PROTEINS FOR FUNCTIONAL AND STRUCTURAL APPLICATIONS

    Toni Kudlicki

    Toni Kudlicki, Staff Scientist, Group Leader Structural Proteomics, Invitrogen

  • Novel cell-free expression systems for structural proteomics
  • Real-time and in-gel detection of protein products with a novel technology
  • Correlation between in vitro and in vivo protein expression
  • E.coli and baculovirus-based protein expression
  • 15:00 Afternoon Tea

    15:20 BACTERIAL EXPRESSION AND CRYSTALLISATION OF MEMBRANE PROTEINS

    Peter Henderson

    Peter Henderson, Professor, Biochemistry & Molecular Biology, University of Leeds

  • Over 40 membrane proteins have been cloned from thirteen species of bacteria so far
  • They are mostly substrate uptake or antibiotic efflux proteins
  • Amplified expression is achieved in E.coli host strains
  • The proteins comprise 10-50% of the inner membrane
  • By fusion with (His)6 or Strep tags purification is achieved
  • Purified proteins are subjected to crystallisation trials
  • Crystals are being obtained that diffract x-rays for structure determination
  • 16:00 PARALLEL PROTEIN PURIFICATION

    Stefan Schmidt

    Stefan Schmidt, Team Leader, Protein Science, AstraZeneca

  • Integrated or modular automation?
  • Overcoming limitations
  • System specifications
  • Current experimental data
  • What will the future look like?
  • 16:40 HIGH-THROUGHPUT PURIFICATION OF SECRETED PROTEINS EXPRESSED IN MAMMALIAN CELLS

    Amanda Proudfoot

    Amanda Proudfoot, Head, Protein Biochemistry, Serono

  • Expression of a large number of secreted proteins
  • Roboticised purification
  • Up to 20 100 ml culture medium samples are purified per day
  • The protein recoveries ranges for undetectable by Western blot to > 1 mg
  • Activities detected at all expression levels
  • Scale up strategies will be discussed
  • 17:20 Chairman’s Closing Remarks and Close of Day One

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    Tauseef Butt

    Tauseef Butt, President, LifeSensors

    9:10 EXPRESSION, PURIFICATION, SPR AND STRUCTURAL STUDIES OF A BRAIN GPCR

    Anthony Watts

    Anthony Watts, Professor, Biochemistry, University of Oxford

  • Membrane receptor
  • Ligand binding
  • SPR
  • Neurotransmitters
  • Ligand structure
  • 9:50 ALPHAVIRUSES

    Kenneth Lundstrom

    Kenneth Lundstrom, Chief Scientific Officer, BioXtal

  • Rapid production of high-titer recombinant viral particles
  • Recombinant protein expression in a broad range of mammalian host cells
  • Expression of 100 G protein-coupled receptors
  • Application of alphaviruses in neurobiology
  • Engineering of less cytotoxic and temperature-sensitive mutant vectors
  • Application of alphavirus vectors for cancer gene therapy
  • 10:30 Morning Coffee

    10:50 MEMBRANE ABSORBERS AND THEIR APPLICATION IN PROTEIN RESEARCH

    Phil Little

    Phil Little, UK Product Manager, Vivascience

  • Removal of abundant contaminating proteins
  • Processing multiple samples
  • Beyond 2D gel analysis
  • 11:30 PEPTIDE DRUG DELIVERY

    Mason Diamond

    Mason Diamond, Vice President, Clinical & Regulatory Affairs, TyRx Pharma

  • Current challenges in peptide drug delivery
  • Current peptide delivery platforms
  • New polymers
  • Peptide drug delivery systems – drug, device, biologic or combination
  • 12:10 Networking Lunch

    13:40 A NEW APPROACH IN PROTEIN REFOLDING

    Daniel Jones

    Daniel Jones, Chief Scientific Officer, Novexin

  • Refolding problems
  • Limitations of current methods
  • Carbohydrate
  • Degradation
  • Case study 1
  • Case study 2
  • 14:20 A SEMI-AUTOMATED PROTEIN REFOLDING PLATFORM

    Paul Ramage

    Paul Ramage, Group Leader, Protein Preparation, Protein Structure Unit, Novartis Institutes for Biomedical Research

  • Producing proteins for structural biology
  • Why in vitro refolding is important
  • Matrix refolding screen
  • Is the protein folded?
  • Choice of read-out
  • Some recent results
  • Unexpected benefits
  • 15:00 Afternoon Tea

    15:20 A REVIEW OF NEW AND ENABLING TECHNOLOGIES FOR MULTI-PARALLEL BACULOVIRUS MEDIATED PROTEIN EXPRESSION

    Ian Hunt

    Ian Hunt, Laboratory Head, Novartis Institutes for Biomedical Research

  • A deep-well block expression system that utilises gateway cloning technology which allows for the rapid cloning and screening of multiple parameters for scale-up
  • Development of fluorescence-based reporter system for monitoring insect cell infection and a micro-fluidic chip based methodology for the calculation of baculovirus titre
  • Development of novel 4-way baculovirus expression plasmids
  • 16:00 PER.C6® AS A PLATFORM FOR MANUFACTURING OF MONOCLONAL ANTIBODIES

    Bram Bout

    Bram Bout, Vice President, Protein Production, Crucell

  • Background of the cell line
  • Selection of high producing clones
  • Fed-batch process
  • Continuous perfusion
  • Quality of the monoclonal antibodies
  • 16:40 SUMO AND SPLIT SUMO FUSION TECHNOLOGY FOR

    Tauseef Butt

    Tauseef Butt, President, LifeSensors

  • SUMO fusions enhance expression and facilitate purification of recombinant proteins
  • SUMO fusions promote solubility of insoluble proteins and restore biological activity
  • Variety of SUMO tags have been developed that function in prokaryotes, insect cells, yeast and mammalian cells
  • Designing gene fusions is sometimes the only way to express difficult proteins
  • SUMO system is superior to GST, MBP, TRX, ubiquitin and NUS A fusion systems
  • SUMO proteases are 100 times more efficient as compared to TEV proteases
  • Desired N-termini can be efficiently generated by SUMO fusion system
  • 17:00 Chairman’s Closing Remarks and Close of Day One

    +

    Workshops

    Millennium Gloucester Hotel

    Harrington Gardens
    London SW7 4LH
    United Kingdom

    Millennium Gloucester Hotel

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.